Pancreatic Enzyme Replacement Therapy (PERT) Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application
By: HDIN Research
Published: 2025-09-21
Pages: 77
Market Research Report Price
- Single User License (1 Users) $ 3,200
- Team License (2~5 Users) $ 4,200
- Corporate License (>5 Users) $ 5,200
Pancreatic Enzyme Replacement Therapy (PERT) Market Summary
The pancreatic enzyme replacement therapy (PERT) market addresses exocrine pancreatic insufficiency (EPI), a maldigestion syndrome arising from deficient secretion of lipase, amylase, and proteases, impairing fat, carbohydrate, and protein breakdown and leading to steatorrhea, weight loss, and nutrient malabsorption. EPI manifests in 36% of chronic pancreatitis diagnoses, escalating to 63% at five years and 94% at ten, with near-universal late-stage occurrence; in severe acute pancreatitis, 19-39% develop EPI as a complication, characterized by diarrhea, bloating, and vitamin deficiencies when lipase falls below 10% capacity. PERT, comprising porcine- or bovine-derived pancrelipase microspheres in enteric-coated capsules, mimics physiologic enzyme delivery by activating in the duodenum's alkaline milieu, restoring 70-90% fat absorption in compliant patients. The market's hallmarks include lipase-unit dosing (500-2,500 units/kg/meal) tailored to dietary fat content, with innovations in microbead technologies minimizing fibrotic adherence and proton-pump inhibitor adjuncts countering gastric inactivation. Real-world adherence hovers at 50-70%, hampered by bulky regimens, yet registries affirm malnutrition reversal in cystic fibrosis and post-pancreatectomy cohorts. By 2025, the global PERT market is estimated to be valued between USD 1.8 billion and USD 3.6 billion, with a projected compound annual growth rate (CAGR) of 2.5% to 4.5% through 2030. This tempered growth mirrors rising EPI burdens from diabetes (22% type 2 overlap) and pancreatic cancers (50-92% prevalence), alongside guideline evolutions from AGA emphasizing fecal elastase screening for early intervention. The sector contends with porcine sourcing ethics and vegan alternatives in pipeline, yet leverages patient-reported outcomes for dose optimization. PERT encapsulates gastroenterology's supportive ethos, mitigating osteoporosis and sarcopenia in chronic cases, though underdiagnosis—10-20% general prevalence—affects 80,000 annual acute pancreatitis-linked instances.
Regional Market Trends
The PERT market varies regionally, driven by pancreatitis incidences, diagnostic sophistication, and reimbursement for chronic malabsorption.
● North America: Foremost with a CAGR of 2.0%–3.5%, this area's strength lies in NIDDK surveillance and Medicare coverage for EPI workups. The United States, the dominant consumer, advances via Creon's stronghold in cystic fibrosis youth, where 85% require lifelong therapy; trends favor delayed-release pearls in obese diabetic cohorts.
● Europe: Solid at a CAGR of 1.8%–3.0%, ESPEN guidelines and EMA approvals harmonize. Germany leads with GKV subsidies for Zenpep in alcoholic pancreatitis (40% EPI), United Kingdom's NHS prioritizing post-surgical dosing; Eastern Europe's rising incidences accelerate generics.
● Asia-Pacific: Accelerating CAGR of 3.5%–5.0%, metabolic shifts amplify. China emerges as the hub, with NMPA nods for Pancreatin capsules amid 20 million chronic pancreatitis cases; Japan's JPS focuses on acute EPI (30% post-pancreatitis).
● Latin America: Growing at CAGR 2.5%–4.0%, PAHO nutrition programs aid. Brazil tops with SUS Creon for tropical pancreatitis clusters, urban Sao Paulo emphasizing lipase titration.
● Middle East and Africa (MEA): Modest CAGR 2.0%–3.5%, aid mitigates. Saudi Arabia progresses via SFDA imports for cystic fibrosis (1:2,500 births), South Africa's NHLS integrates for HIV-pancreatitis overlaps.
Application Analysis
The PERT market focuses on exocrine pancreatic insufficiency as its core application, with subtypes by etiology influencing dosing and monitoring.
● Exocrine Pancreatic Insufficiency: This singular yet heterogeneous application sustains a CAGR of 2.5%–4.5%, encompassing chronic pancreatitis (36-100% progression), severe acute pancreatitis (19-39% complication), cystic fibrosis (85% adolescents), and pancreatic cancer (50-92%). Features include lipase-dominant formulations (pancrelipase 4:1:1 ratio) for fat malabsorption primacy, with trends toward meal-specific apps calculating 10,000 units/g fat; developments spotlight vegan microbial enzymes and nanoparticle coatings for ileal release, addressing 72% inconsistent adherence.
Company Profiles
● AbbVie: Creon (pancrelipase) achieved USD 1.2–1.6 billion in 2024 U.S. revenues, monopolizing domestic sales with microsphere tech; AbbVie's GI focus extends cystic fibrosis partnerships.
● Viatris: Generic Creon posted USD 0.3–0.4 billion in 2024, eroding originator via AB equivalence; Viatris's scale aids global tenders.
● Nestlé: Zenpep (pancrelipase) delayed-release capsules target pediatric EPI, leveraging Nestlé's nutrition heritage for flavored variants.
● Digestive Care Inc.: Pertzye (pancrelipase) innovates bicarbonate buffering for acid-prone, carving cystic fibrosis niche.
● VIVUS LLC: Pancreaze (pancrelipase) emphasizes high-lipase potency, with access programs for uninsured.
● Chongqing Aoli Biopharmaceutical Co. Ltd.: Pancreatin Enteric Capsules serve Asia's chronic pancreatitis surge, affordable bovine sourcing.
Industry Value Chain Analysis
The PERT value chain melds enzymatic extraction with nutritional counseling, from porcine pancreas procurement to malabsorption metrics. Upstream R&D employs zymography for activity assays, stability in pH 5-7 gradients; porcine ethics drive recombinant pilots, costs USD 100 million offset by orphan cystic fibrosis nods. Clinicals use 72-hour fecal fat quant per AGA, adaptive dosing trials, FDA's QIDP expediting. Midstream harvests pancreata via abattoir chains, lipase enrichment via chromatography to 200,000 USP units/g; enteric microencapsulation in HPMC shells, Indian CMOs scaling 50 tons. Formulation beads 1-2mm for mixing, bottled with desiccants. Downstream ambient logistics to GI clinics, AbbVie's direct-ship for stability. Marketing via DDW symposia on fecal elastase, HEOR via $30,000/QALY malnutrition aversion. Support includes dietitian apps and vitamin assays, FAERS for fibrosing colonopathy. Verticals like AbbVie integrate from sourcing to registries.
Opportunities and Challenges
Opportunities:
● EPI Screening Booms: Fecal elastase in diabetes unlocks 22% overlap, $1B volumes via point-of-care.
● Pediatric Formulations: Flavored pearls boost 50% adherence in CF, orphan expansions.
● Vegan Alternatives: Microbial enzymes tap ethical markets, Asia growth.
● Combo Nutraceuticals: With PPIs for GERD-EPI, halving doses.
Challenges:
● Adherence Hurdles: Bulky 8-capsule meals deter 72%, needing miniaturized.
● Sourcing Volatilities: Porcine shortages inflate 20%, BSE risks.
● Underdiagnosis: 10-20% prevalence missed, rural voids.
● Cost Pressures: $5,000/year burdens uninsured, generics lagging.
The pancreatic enzyme replacement therapy (PERT) market addresses exocrine pancreatic insufficiency (EPI), a maldigestion syndrome arising from deficient secretion of lipase, amylase, and proteases, impairing fat, carbohydrate, and protein breakdown and leading to steatorrhea, weight loss, and nutrient malabsorption. EPI manifests in 36% of chronic pancreatitis diagnoses, escalating to 63% at five years and 94% at ten, with near-universal late-stage occurrence; in severe acute pancreatitis, 19-39% develop EPI as a complication, characterized by diarrhea, bloating, and vitamin deficiencies when lipase falls below 10% capacity. PERT, comprising porcine- or bovine-derived pancrelipase microspheres in enteric-coated capsules, mimics physiologic enzyme delivery by activating in the duodenum's alkaline milieu, restoring 70-90% fat absorption in compliant patients. The market's hallmarks include lipase-unit dosing (500-2,500 units/kg/meal) tailored to dietary fat content, with innovations in microbead technologies minimizing fibrotic adherence and proton-pump inhibitor adjuncts countering gastric inactivation. Real-world adherence hovers at 50-70%, hampered by bulky regimens, yet registries affirm malnutrition reversal in cystic fibrosis and post-pancreatectomy cohorts. By 2025, the global PERT market is estimated to be valued between USD 1.8 billion and USD 3.6 billion, with a projected compound annual growth rate (CAGR) of 2.5% to 4.5% through 2030. This tempered growth mirrors rising EPI burdens from diabetes (22% type 2 overlap) and pancreatic cancers (50-92% prevalence), alongside guideline evolutions from AGA emphasizing fecal elastase screening for early intervention. The sector contends with porcine sourcing ethics and vegan alternatives in pipeline, yet leverages patient-reported outcomes for dose optimization. PERT encapsulates gastroenterology's supportive ethos, mitigating osteoporosis and sarcopenia in chronic cases, though underdiagnosis—10-20% general prevalence—affects 80,000 annual acute pancreatitis-linked instances.
Regional Market Trends
The PERT market varies regionally, driven by pancreatitis incidences, diagnostic sophistication, and reimbursement for chronic malabsorption.
● North America: Foremost with a CAGR of 2.0%–3.5%, this area's strength lies in NIDDK surveillance and Medicare coverage for EPI workups. The United States, the dominant consumer, advances via Creon's stronghold in cystic fibrosis youth, where 85% require lifelong therapy; trends favor delayed-release pearls in obese diabetic cohorts.
● Europe: Solid at a CAGR of 1.8%–3.0%, ESPEN guidelines and EMA approvals harmonize. Germany leads with GKV subsidies for Zenpep in alcoholic pancreatitis (40% EPI), United Kingdom's NHS prioritizing post-surgical dosing; Eastern Europe's rising incidences accelerate generics.
● Asia-Pacific: Accelerating CAGR of 3.5%–5.0%, metabolic shifts amplify. China emerges as the hub, with NMPA nods for Pancreatin capsules amid 20 million chronic pancreatitis cases; Japan's JPS focuses on acute EPI (30% post-pancreatitis).
● Latin America: Growing at CAGR 2.5%–4.0%, PAHO nutrition programs aid. Brazil tops with SUS Creon for tropical pancreatitis clusters, urban Sao Paulo emphasizing lipase titration.
● Middle East and Africa (MEA): Modest CAGR 2.0%–3.5%, aid mitigates. Saudi Arabia progresses via SFDA imports for cystic fibrosis (1:2,500 births), South Africa's NHLS integrates for HIV-pancreatitis overlaps.
Application Analysis
The PERT market focuses on exocrine pancreatic insufficiency as its core application, with subtypes by etiology influencing dosing and monitoring.
● Exocrine Pancreatic Insufficiency: This singular yet heterogeneous application sustains a CAGR of 2.5%–4.5%, encompassing chronic pancreatitis (36-100% progression), severe acute pancreatitis (19-39% complication), cystic fibrosis (85% adolescents), and pancreatic cancer (50-92%). Features include lipase-dominant formulations (pancrelipase 4:1:1 ratio) for fat malabsorption primacy, with trends toward meal-specific apps calculating 10,000 units/g fat; developments spotlight vegan microbial enzymes and nanoparticle coatings for ileal release, addressing 72% inconsistent adherence.
Company Profiles
● AbbVie: Creon (pancrelipase) achieved USD 1.2–1.6 billion in 2024 U.S. revenues, monopolizing domestic sales with microsphere tech; AbbVie's GI focus extends cystic fibrosis partnerships.
● Viatris: Generic Creon posted USD 0.3–0.4 billion in 2024, eroding originator via AB equivalence; Viatris's scale aids global tenders.
● Nestlé: Zenpep (pancrelipase) delayed-release capsules target pediatric EPI, leveraging Nestlé's nutrition heritage for flavored variants.
● Digestive Care Inc.: Pertzye (pancrelipase) innovates bicarbonate buffering for acid-prone, carving cystic fibrosis niche.
● VIVUS LLC: Pancreaze (pancrelipase) emphasizes high-lipase potency, with access programs for uninsured.
● Chongqing Aoli Biopharmaceutical Co. Ltd.: Pancreatin Enteric Capsules serve Asia's chronic pancreatitis surge, affordable bovine sourcing.
Industry Value Chain Analysis
The PERT value chain melds enzymatic extraction with nutritional counseling, from porcine pancreas procurement to malabsorption metrics. Upstream R&D employs zymography for activity assays, stability in pH 5-7 gradients; porcine ethics drive recombinant pilots, costs USD 100 million offset by orphan cystic fibrosis nods. Clinicals use 72-hour fecal fat quant per AGA, adaptive dosing trials, FDA's QIDP expediting. Midstream harvests pancreata via abattoir chains, lipase enrichment via chromatography to 200,000 USP units/g; enteric microencapsulation in HPMC shells, Indian CMOs scaling 50 tons. Formulation beads 1-2mm for mixing, bottled with desiccants. Downstream ambient logistics to GI clinics, AbbVie's direct-ship for stability. Marketing via DDW symposia on fecal elastase, HEOR via $30,000/QALY malnutrition aversion. Support includes dietitian apps and vitamin assays, FAERS for fibrosing colonopathy. Verticals like AbbVie integrate from sourcing to registries.
Opportunities and Challenges
Opportunities:
● EPI Screening Booms: Fecal elastase in diabetes unlocks 22% overlap, $1B volumes via point-of-care.
● Pediatric Formulations: Flavored pearls boost 50% adherence in CF, orphan expansions.
● Vegan Alternatives: Microbial enzymes tap ethical markets, Asia growth.
● Combo Nutraceuticals: With PPIs for GERD-EPI, halving doses.
Challenges:
● Adherence Hurdles: Bulky 8-capsule meals deter 72%, needing miniaturized.
● Sourcing Volatilities: Porcine shortages inflate 20%, BSE risks.
● Underdiagnosis: 10-20% prevalence missed, rural voids.
● Cost Pressures: $5,000/year burdens uninsured, generics lagging.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Pancreatic Enzyme Replacement Therapy (PERT) Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Pancreatic Enzyme Replacement Therapy (PERT) Market in North America (2020-2030)
8.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
8.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
8.3 Competition by Players/Suppliers
8.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Pancreatic Enzyme Replacement Therapy (PERT) Market in South America (2020-2030)
9.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
9.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
9.3 Competition by Players/Suppliers
9.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Pancreatic Enzyme Replacement Therapy (PERT) Market in Asia & Pacific (2020-2030)
10.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
10.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
10.3 Competition by Players/Suppliers
10.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Pancreatic Enzyme Replacement Therapy (PERT) Market in Europe (2020-2030)
11.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
11.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
11.3 Competition by Players/Suppliers
11.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Pancreatic Enzyme Replacement Therapy (PERT) Market in MEA (2020-2030)
12.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
12.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
12.3 Competition by Players/Suppliers
12.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Pancreatic Enzyme Replacement Therapy (PERT) Market (2020-2025)
13.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
13.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
13.3 Competition by Players/Suppliers
13.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Chapter 14 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Forecast (2025-2030)
14.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size Forecast
14.2 Pancreatic Enzyme Replacement Therapy (PERT) Application Forecast
14.3 Competition by Players/Suppliers
14.4 Pancreatic Enzyme Replacement Therapy (PERT) Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 AbbVie
15.1.1 Company Profile
15.1.2 Main Business and Pancreatic Enzyme Replacement Therapy (PERT) Information
15.1.3 SWOT Analysis of AbbVie
15.1.4 AbbVie Pancreatic Enzyme Replacement Therapy (PERT) Sales, Revenue, Price and Gross Margin (2020-2025)
15.2 Viatris
15.2.1 Company Profile
15.2.2 Main Business and Pancreatic Enzyme Replacement Therapy (PERT) Information
15.2.3 SWOT Analysis of Viatris
15.2.4 Viatris Pancreatic Enzyme Replacement Therapy (PERT) Sales, Revenue, Price and Gross Margin (2020-2025)
15.3 Nestlé
15.3.1 Company Profile
15.3.2 Main Business and Pancreatic Enzyme Replacement Therapy (PERT) Information
15.3.3 SWOT Analysis of Nestlé
15.3.4 Nestlé Pancreatic Enzyme Replacement Therapy (PERT) Sales, Revenue, Price and Gross Margin (2020-2025)
15.4 Digestive Care Inc.
15.4.1 Company Profile
15.4.2 Main Business and Pancreatic Enzyme Replacement Therapy (PERT) Information
15.4.3 SWOT Analysis of Digestive Care Inc.
15.4.4 Digestive Care Inc. Pancreatic Enzyme Replacement Therapy (PERT) Sales, Revenue, Price and Gross Margin (2020-2025)
15.5 VIVUS LLC
15.5.1 Company Profile
15.5.2 Main Business and Pancreatic Enzyme Replacement Therapy (PERT) Information
15.5.3 SWOT Analysis of VIVUS LLC
15.5.4 VIVUS LLC Pancreatic Enzyme Replacement Therapy (PERT) Sales, Revenue, Price and Gross Margin (2020-2025)
Please ask for sample pages for full companies list
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Pancreatic Enzyme Replacement Therapy (PERT) Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Pancreatic Enzyme Replacement Therapy (PERT) Market in North America (2020-2030)
8.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
8.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
8.3 Competition by Players/Suppliers
8.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Pancreatic Enzyme Replacement Therapy (PERT) Market in South America (2020-2030)
9.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
9.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
9.3 Competition by Players/Suppliers
9.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Pancreatic Enzyme Replacement Therapy (PERT) Market in Asia & Pacific (2020-2030)
10.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
10.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
10.3 Competition by Players/Suppliers
10.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Pancreatic Enzyme Replacement Therapy (PERT) Market in Europe (2020-2030)
11.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
11.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
11.3 Competition by Players/Suppliers
11.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Pancreatic Enzyme Replacement Therapy (PERT) Market in MEA (2020-2030)
12.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
12.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
12.3 Competition by Players/Suppliers
12.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Pancreatic Enzyme Replacement Therapy (PERT) Market (2020-2025)
13.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size
13.2 Pancreatic Enzyme Replacement Therapy (PERT) Market by End Use
13.3 Competition by Players/Suppliers
13.4 Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Chapter 14 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Forecast (2025-2030)
14.1 Pancreatic Enzyme Replacement Therapy (PERT) Market Size Forecast
14.2 Pancreatic Enzyme Replacement Therapy (PERT) Application Forecast
14.3 Competition by Players/Suppliers
14.4 Pancreatic Enzyme Replacement Therapy (PERT) Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 AbbVie
15.1.1 Company Profile
15.1.2 Main Business and Pancreatic Enzyme Replacement Therapy (PERT) Information
15.1.3 SWOT Analysis of AbbVie
15.1.4 AbbVie Pancreatic Enzyme Replacement Therapy (PERT) Sales, Revenue, Price and Gross Margin (2020-2025)
15.2 Viatris
15.2.1 Company Profile
15.2.2 Main Business and Pancreatic Enzyme Replacement Therapy (PERT) Information
15.2.3 SWOT Analysis of Viatris
15.2.4 Viatris Pancreatic Enzyme Replacement Therapy (PERT) Sales, Revenue, Price and Gross Margin (2020-2025)
15.3 Nestlé
15.3.1 Company Profile
15.3.2 Main Business and Pancreatic Enzyme Replacement Therapy (PERT) Information
15.3.3 SWOT Analysis of Nestlé
15.3.4 Nestlé Pancreatic Enzyme Replacement Therapy (PERT) Sales, Revenue, Price and Gross Margin (2020-2025)
15.4 Digestive Care Inc.
15.4.1 Company Profile
15.4.2 Main Business and Pancreatic Enzyme Replacement Therapy (PERT) Information
15.4.3 SWOT Analysis of Digestive Care Inc.
15.4.4 Digestive Care Inc. Pancreatic Enzyme Replacement Therapy (PERT) Sales, Revenue, Price and Gross Margin (2020-2025)
15.5 VIVUS LLC
15.5.1 Company Profile
15.5.2 Main Business and Pancreatic Enzyme Replacement Therapy (PERT) Information
15.5.3 SWOT Analysis of VIVUS LLC
15.5.4 VIVUS LLC Pancreatic Enzyme Replacement Therapy (PERT) Sales, Revenue, Price and Gross Margin (2020-2025)
Please ask for sample pages for full companies list
Table Abbreviation and Acronyms
Table Research Scope of Pancreatic Enzyme Replacement Therapy (PERT) Report
Table Data Sources of Pancreatic Enzyme Replacement Therapy (PERT) Report
Table Major Assumptions of Pancreatic Enzyme Replacement Therapy (PERT) Report
Table Pancreatic Enzyme Replacement Therapy (PERT) Classification
Table Pancreatic Enzyme Replacement Therapy (PERT) Applications
Table Drivers of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Restraints of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Opportunities of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Threats of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Raw Materials Suppliers
Table Different Production Methods of Pancreatic Enzyme Replacement Therapy (PERT)
Table Cost Structure Analysis of Pancreatic Enzyme Replacement Therapy (PERT)
Table Key End Users
Table Latest News of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Merger and Acquisition
Table Planned/Future Project of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Policy of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table 2020-2030 North America Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 North America Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 North America Pancreatic Enzyme Replacement Therapy (PERT) Key Players Revenue
Table 2020-2025 North America Pancreatic Enzyme Replacement Therapy (PERT) Key Players Market Share
Table 2020-2030 North America Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2030 United States Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Canada Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Mexico Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 South America Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 South America Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 South America Pancreatic Enzyme Replacement Therapy (PERT) Key Players Revenue
Table 2020-2025 South America Pancreatic Enzyme Replacement Therapy (PERT) Key Players Market Share
Table 2020-2030 South America Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2030 Brazil Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Argentina Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Chile Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Peru Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Key Players Revenue
Table 2020-2025 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Key Players Market Share
Table 2020-2030 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2030 China Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 India Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Japan Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 South Korea Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Southeast Asia Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Australia Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Europe Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Europe Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 Europe Pancreatic Enzyme Replacement Therapy (PERT) Key Players Revenue
Table 2020-2025 Europe Pancreatic Enzyme Replacement Therapy (PERT) Key Players Market Share
Table 2020-2030 Europe Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2030 Germany Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 France Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 United Kingdom Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Italy Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Spain Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Belgium Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Netherlands Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Austria Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Poland Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Russia Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 MEA Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 MEA Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 MEA Pancreatic Enzyme Replacement Therapy (PERT) Key Players Revenue
Table 2020-2025 MEA Pancreatic Enzyme Replacement Therapy (PERT) Key Players Market Share
Table 2020-2030 MEA Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2030 Egypt Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Israel Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 South Africa Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Gulf Cooperation Council Countries Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Turkey Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Region
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size Share by Region
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Share by Application
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Key Vendors Revenue
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Key Vendors Market Share
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Share by Type
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Region
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size Share by Region
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Share by Application
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Key Vendors Revenue
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Key Vendors Market Share
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2025-2030 Pancreatic Enzyme Replacement Therapy (PERT) Global Market Share by Type
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Pancreatic Enzyme Replacement Therapy (PERT) Picture
Figure 2020-2030 North America Pancreatic Enzyme Replacement Therapy (PERT) Market Size and CAGR
Figure 2020-2030 South America Pancreatic Enzyme Replacement Therapy (PERT) Market Size and CAGR
Figure 2020-2030 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Market Size and CAGR
Figure 2020-2030 Europe Pancreatic Enzyme Replacement Therapy (PERT) Market Size and CAGR
Figure 2020-2030 MEA Pancreatic Enzyme Replacement Therapy (PERT) Market Size and CAGR
Figure 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size and Growth Rate
Figure 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size and Growth Rate
Table Research Scope of Pancreatic Enzyme Replacement Therapy (PERT) Report
Table Data Sources of Pancreatic Enzyme Replacement Therapy (PERT) Report
Table Major Assumptions of Pancreatic Enzyme Replacement Therapy (PERT) Report
Table Pancreatic Enzyme Replacement Therapy (PERT) Classification
Table Pancreatic Enzyme Replacement Therapy (PERT) Applications
Table Drivers of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Restraints of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Opportunities of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Threats of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Raw Materials Suppliers
Table Different Production Methods of Pancreatic Enzyme Replacement Therapy (PERT)
Table Cost Structure Analysis of Pancreatic Enzyme Replacement Therapy (PERT)
Table Key End Users
Table Latest News of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Merger and Acquisition
Table Planned/Future Project of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table Policy of Pancreatic Enzyme Replacement Therapy (PERT) Market
Table 2020-2030 North America Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 North America Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 North America Pancreatic Enzyme Replacement Therapy (PERT) Key Players Revenue
Table 2020-2025 North America Pancreatic Enzyme Replacement Therapy (PERT) Key Players Market Share
Table 2020-2030 North America Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2030 United States Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Canada Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Mexico Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 South America Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 South America Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 South America Pancreatic Enzyme Replacement Therapy (PERT) Key Players Revenue
Table 2020-2025 South America Pancreatic Enzyme Replacement Therapy (PERT) Key Players Market Share
Table 2020-2030 South America Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2030 Brazil Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Argentina Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Chile Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Peru Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Key Players Revenue
Table 2020-2025 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Key Players Market Share
Table 2020-2030 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2030 China Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 India Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Japan Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 South Korea Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Southeast Asia Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Australia Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Europe Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Europe Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 Europe Pancreatic Enzyme Replacement Therapy (PERT) Key Players Revenue
Table 2020-2025 Europe Pancreatic Enzyme Replacement Therapy (PERT) Key Players Market Share
Table 2020-2030 Europe Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2030 Germany Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 France Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 United Kingdom Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Italy Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Spain Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Belgium Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Netherlands Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Austria Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Poland Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Russia Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 MEA Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 MEA Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 MEA Pancreatic Enzyme Replacement Therapy (PERT) Key Players Revenue
Table 2020-2025 MEA Pancreatic Enzyme Replacement Therapy (PERT) Key Players Market Share
Table 2020-2030 MEA Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2030 Egypt Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Israel Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 South Africa Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Gulf Cooperation Council Countries Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2030 Turkey Pancreatic Enzyme Replacement Therapy (PERT) Market Size
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Region
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size Share by Region
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Share by Application
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Key Vendors Revenue
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Key Vendors Market Share
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Share by Type
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Region
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size Share by Region
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Application
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Share by Application
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Key Vendors Revenue
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Key Vendors Market Share
Table 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size by Type
Table 2025-2030 Pancreatic Enzyme Replacement Therapy (PERT) Global Market Share by Type
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Pancreatic Enzyme Replacement Therapy (PERT) Picture
Figure 2020-2030 North America Pancreatic Enzyme Replacement Therapy (PERT) Market Size and CAGR
Figure 2020-2030 South America Pancreatic Enzyme Replacement Therapy (PERT) Market Size and CAGR
Figure 2020-2030 Asia & Pacific Pancreatic Enzyme Replacement Therapy (PERT) Market Size and CAGR
Figure 2020-2030 Europe Pancreatic Enzyme Replacement Therapy (PERT) Market Size and CAGR
Figure 2020-2030 MEA Pancreatic Enzyme Replacement Therapy (PERT) Market Size and CAGR
Figure 2020-2025 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size and Growth Rate
Figure 2025-2030 Global Pancreatic Enzyme Replacement Therapy (PERT) Market Size and Growth Rate
Research Methodology
- Market Estimated Methodology:
Bottom-up & top-down approach, supply & demand approach are the most important method which is used by HDIN Research to estimate the market size.
1）Top-down & Bottom-up Approach
Top-down approach uses a general market size figure and determines the percentage that the objective market represents.
Bottom-up approach size the objective market by collecting the sub-segment information.
2）Supply & Demand Approach
Supply approach is based on assessments of the size of each competitor supplying the objective market.
Demand approach combine end-user data within a market to estimate the objective market size. It is sometimes referred to as bottom-up approach.
- Forecasting Methodology
- Numerous factors impacting the market trend are considered for forecast model:
- New technology and application in the future;
- New project planned/under contraction;
- Global and regional underlying economic growth;
- Threatens of substitute products;
- Industry expert opinion;
- Policy and Society implication.
- Analysis Tools
1）PEST Analysis
PEST Analysis is a simple and widely used tool that helps our client analyze the Political, Economic, Socio-Cultural, and Technological changes in their business environment.
- Benefits of a PEST analysis:
- It helps you to spot business opportunities, and it gives you advanced warning of significant threats.
- It reveals the direction of change within your business environment. This helps you shape what you’re doing, so that you work with change, rather than against it.
- It helps you avoid starting projects that are likely to fail, for reasons beyond your control.
- It can help you break free of unconscious assumptions when you enter a new country, region, or market; because it helps you develop an objective view of this new environment.
2）Porter’s Five Force Model Analysis
The Porter’s Five Force Model is a tool that can be used to analyze the opportunities and overall competitive advantage. The five forces that can assist in determining the competitive intensity and potential attractiveness within a specific area.
- Threat of New Entrants: Profitable industries that yield high returns will attract new firms.
- Threat of Substitutes: A substitute product uses a different technology to try to solve the same economic need.
- Bargaining Power of Customers: the ability of customers to put the firm under pressure, which also affects the customer's sensitivity to price changes.
- Bargaining Power of Suppliers: Suppliers of raw materials, components, labor, and services (such as expertise) to the firm can be a source of power over the firm when there are few substitutes.
- Competitive Rivalry: For most industries the intensity of competitive rivalry is the major determinant of the competitiveness of the industry.
3）Value Chain Analysis
Value chain analysis is a tool to identify activities, within and around the firm and relating these activities to an assessment of competitive strength. Value chain can be analyzed by primary activities and supportive activities. Primary activities include: inbound logistics, operations, outbound logistics, marketing & sales, service. Support activities include: technology development, human resource management, management, finance, legal, planning.
4）SWOT Analysis
SWOT analysis is a tool used to evaluate a company's competitive position by identifying its strengths, weaknesses, opportunities and threats. The strengths and weakness is the inner factor; the opportunities and threats are the external factor. By analyzing the inner and external factors, the analysis can provide the detail information of the position of a player and the characteristics of the industry.
- Strengths describe what the player excels at and separates it from the competition
- Weaknesses stop the player from performing at its optimum level.
- Opportunities refer to favorable external factors that the player can use to give it a competitive advantage.
- Threats refer to factors that have the potential to harm the player.
- Data Sources
| Primary Sources | Secondary Sources |
|---|---|
| Face to face/Phone Interviews with market participants, such as: Manufactures; Distributors; End-users; Experts. Online Survey |
Government/International Organization Data: Annual Report/Presentation/Fact Book Internet Source Information Industry Association Data Free/Purchased Database Market Research Report Book/Journal/News |